SGLT2 inhibitors and GLP1 receptor antagonists improve type-2 diabetes outcomes, but are not cost effective
$500M-plus from opioid deal starts heading to Washington
4 October 2022WHO warns Haiti cholera toll could rise
4 October 2022SGLT2 inhibitors and GLP1 receptor antagonists improve type-2 diabetes outcomes, but are not cost effective
A cost-effectiveness study of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists has found that the use of these medications as first-line treatment for type-2 diabetes would improve outcomes, but their costs would need to decrease by at least 70 percent to be cost-effective. The study is published in Annals of Internal Medicine.
